HTT and Huntington disease: There is increasing evidence that HDAC inhibitors may represent a useful class of therapeutic agents for HD: For example, in transgenic mouse models of HD, the HDAC class IIa isoform HDAC4 associates with mutant HTT protein and colocalizes with cytoplasmic aggregates.